scholarly journals Treatment of Hepatic Epithelioid Hemangioendothelioma: Finding Uses for Thalidomide in a New Era of Medicine

2015 ◽  
Vol 2015 ◽  
pp. 1-4 ◽  
Author(s):  
Matthew P. Soape ◽  
Rashmi Verma ◽  
J. Drew Payne ◽  
Mitchell Wachtel ◽  
Fred Hardwicke ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Liver Biopsy ◽  
Birth Defects ◽  
Epithelioid Hemangioendothelioma ◽  
Vascular Tumors ◽  
Vascular Endothelial ◽  
New Era ◽  
Progression Of Disease ◽  
Endothelial Growth Factor

Hepatic epithelioid hemangioendothelioma (HEH) is extremely rare, occurring in 1 to 2 per 100,000, with chemotherapy options not well defined. Our case involved a 49-year-old female who had hepatic masses and metastasis to the lungs with a liver biopsy revealing HEH. After developing a rash from sorafenib, thalidomide was started with the progression of disease stabilized. Resection is only an option in 10% of the cases; therefore, chemotherapy is the only line of treatment. Newer chemotherapy alternatives are targeting angiogenesis via the vascular endothelial growth factor. Thalidomide was first used as an antiemetic, but, sadly, soon linked to phocomelia birth defects. Given the mechanism of action against angiogenesis, thalidomide has a valid role in vascular tumors. In conclusion, the use of thalidomide as chemotherapy is novel and promising, especially in the setting of a rare vascular liver tumor such as HEH.

scholarly journals Morphological and Immunohistochemical Description of a Splenic Haemangioma in a Captive European Wolf (Canis lupus lupus) and a Review of the Current Literature

2020 ◽  
Vol 7 (3) ◽  
pp. 102
Author(s):  
Josep Maria Monné Rodríguez ◽  
Federico Morandi ◽  
Paolo Cavicchio ◽  
Alessandro Poli ◽  
Ranieri Verin
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Canis Lupus ◽  
Smooth Muscle Actin ◽  
Vascular Tumors ◽  
Vascular Endothelial ◽  
Canis Lupus Familiaris ◽  
Alpha Smooth Muscle Actin ◽  
Factor C ◽  
Endothelial Growth Factor

Neoplastic diseases are rarely described in wild carnivores; only a few reports have been published on this topic. Here, we describe the histological and immunohistochemical features of a haemangioma in the spleen of a grey wolf (Canis lupus lupus) and we compare the results with the dog (Canis lupus familiaris). Additionally, we list the different publications found in the literature with neoplastic lesions in wolves. Our results show similar immunohistochemical features to dogs, in which neoplastic cells express Vimentin, von Willebrand factor, alpha smooth muscle actin antibody, vascular endothelial growth factor C and low vascular endothelial growth factor receptor 3. Toluidine blue special stain shows moderated increased numbers of mast cells infiltrating the tumor, a feature observed in benign vascular tumors in domestic dogs, but not in the malignant counterparts. To our knowledge, this is the first article describing the gross, histological and immunohistochemical features of a splenic haemangioma in a wolf.

Coexpression of Erythropoietin and Vascular Endothelial Growth Factor in Nervous System Tumors Associated With von Hippel-Lindau Tumor Suppressor Gene Loss of Function

Blood ◽  
1998 ◽  
Vol 92 (9) ◽  
pp. 3388-3393 ◽  
Author(s):  
Marion Krieg ◽  
Hugo H. Marti ◽  
Karl H. Plate
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Nervous System ◽  
Growth Factor ◽  
Tumor Suppressor ◽  
Tumor Suppressor Gene ◽  
Suppressor Gene ◽  
Vascular Tumors ◽  
Vascular Endothelial ◽  
Von Hippel Lindau ◽  
Endothelial Growth Factor

Abstract Hemangioblastomas are highly vascular tumors of the central nervous system that overexpress the hypoxia-inducible gene, vascular endothelial growth factor (VEGF), as a consequence of mutational inactivation of the von Hippel-Lindau tumor suppressor gene (VHL). Previous reports showed that hemangioblastomas can also express erythropoietin (Epo), which is also hypoxia-inducible. However, Epo expression in hemangioblastomas was observed only in individual cases, and the analyses were mainly based on indirect determination of erythropoiesis-stimulating activity. Therefore, we analyzed a series of 11 hemangioblastomas for Epo, VEGF, and VHL expression by Northern blot analysis and compared the results with normal brain and glioblastomas. Surprisingly, we observed Epo mRNA expression in all hemangioblastoma specimens analyzed, but in none of four glioblastomas. In contrast, VEGF mRNA was expressed in all hemangioblastomas and all glioblastomas. In situ hybridization revealed neoplastic stromal cells as Epo- and VEGF-producing cells in hemangioblastomas. These results suggest that in the nonhypoxic microenvironment of hemangioblastoma, Epo, similar to VEGF, might be negatively regulated by the VHL gene product. © 1998 by The American Society of Hematology.

Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti–vascular endothelial growth factor receptor therapy

Blood ◽  
2002 ◽  
Vol 99 (10) ◽  
pp. 3851-3853 ◽  
Author(s):  
Stéphane Richard ◽  
Laure Croisille ◽  
Jeannine Yvart ◽  
Nicole Casadeval ◽  
Pascal Eschwège ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Familial Cancer ◽  
Vascular Tumors ◽  
Vegf Receptor ◽  
Vascular Endothelial ◽  
Von Hippel Lindau ◽  
Anti Vegf ◽  
Endothelial Growth Factor ◽  
Secondary Polycythemia

Von Hippel-Lindau (VHL) disease is a dominantly inherited familial cancer syndrome caused by germline mutations in the VHL tumor-suppressor gene. Central nervous system (CNS) and retinal hemangioblastomas are highly vascular tumors that are hallmarks of the disease. These tumors overexpress vascular endothelial growth factor (VEGF) and represent a potential target for anti-angiogenic drugs. We observed, after 3 to 4 months of treatment, secondary paradoxical polycythemia in 3 VHL patients with CNS or retinal hemangioblastomas treated by the anti-VEGF receptor SU5416. Hematocrit was normal before the beginning of the trial, and no progression of hemangioblastomas was observed. Polycythemia vera and all known causes of secondary polycythemia were also ruled out. Polycythemia has never been reported in current SU5416 trials for advanced malignancies and could express a specific action on red blood cell precursors occurring only in the absence of a functional VHL gene. These findings could also affect the inclusion of VHL patients with pre-existing polycythemia in future anti-VEGF receptor trials.

Coexpression of Erythropoietin and Vascular Endothelial Growth Factor in Nervous System Tumors Associated With von Hippel-Lindau Tumor Suppressor Gene Loss of Function

Blood ◽  
1998 ◽  
Vol 92 (9) ◽  
pp. 3388-3393 ◽  
Author(s):  
Marion Krieg ◽  
Hugo H. Marti ◽  
Karl H. Plate
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Nervous System ◽  
Growth Factor ◽  
Tumor Suppressor ◽  
Tumor Suppressor Gene ◽  
Suppressor Gene ◽  
Vascular Tumors ◽  
Vascular Endothelial ◽  
Von Hippel Lindau ◽  
Endothelial Growth Factor

Hemangioblastomas are highly vascular tumors of the central nervous system that overexpress the hypoxia-inducible gene, vascular endothelial growth factor (VEGF), as a consequence of mutational inactivation of the von Hippel-Lindau tumor suppressor gene (VHL). Previous reports showed that hemangioblastomas can also express erythropoietin (Epo), which is also hypoxia-inducible. However, Epo expression in hemangioblastomas was observed only in individual cases, and the analyses were mainly based on indirect determination of erythropoiesis-stimulating activity. Therefore, we analyzed a series of 11 hemangioblastomas for Epo, VEGF, and VHL expression by Northern blot analysis and compared the results with normal brain and glioblastomas. Surprisingly, we observed Epo mRNA expression in all hemangioblastoma specimens analyzed, but in none of four glioblastomas. In contrast, VEGF mRNA was expressed in all hemangioblastomas and all glioblastomas. In situ hybridization revealed neoplastic stromal cells as Epo- and VEGF-producing cells in hemangioblastomas. These results suggest that in the nonhypoxic microenvironment of hemangioblastoma, Epo, similar to VEGF, might be negatively regulated by the VHL gene product. © 1998 by The American Society of Hematology.

scholarly journals Expression of the Vascular Endothelial Growth Factor C Receptor VEGFR-3 in Lymphatic Endothelium of the Skin and in Vascular Tumors

1998 ◽  
Vol 153 (2) ◽  
pp. 395-403 ◽  
Author(s):  
Athina Lymboussaki ◽  
Taina A. Partanen ◽  
Birgitta Olofsson ◽  
Judith Thomas-Crusells ◽  
Christopher D.M. Fletcher ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Vascular Tumors ◽  
Vascular Endothelial ◽  
Lymphatic Endothelium ◽  
Factor C ◽  
Endothelial Growth Factor
Sign in / Sign up

Export Citation Format

Share Document